The Trump administration has prepared an order that would impose 100% tariffs on imports of patented medications and their active ingredients, according to a STAT report citing a draft obtained in Washington. The announcement could come as soon as Thursday, with potential changes possible to timing or scope. The proposal, if finalized, would directly affect pharmaceutical supply chains and pricing for branded, patented products—creating new uncertainty for manufacturers and downstream distributors. It also raises operational questions for companies with outsourced drug substance production or cross-border finished-dose manufacturing. A White House response was not immediately available in the report, leaving businesses to prepare for scenarios where tariff coverage, exemptions, and effective dates could shift quickly. For biotech stakeholders, the policy is notable less for clinical impact and more for near-term commercial and margin risk across the marketed drug base.